Science Pool

HCS Approach for Detection of Genotoxic Aneugens and Clastogens

Posted by Evotec on Feb 11, 2021 7:59:24 PM

Genotoxicity is a key concern during drug discovery and development. Clastogens and aneugens are two types of mutagens which result in chromosomal aberrations. Clastogens directly damage the chromosome causing sections of the DNA being deleted, added or rearranged (structural chromosomal aberrations). Aneugens cause an abnormal number of chromosomes (numerical chromosomal aberrations). Early stage screening of genotoxicity potential along with identification of the mechanism of action of the genotoxicity is important in reducing late stage failure.

In this poster, we focus on:

  • a modified HCS assay for detecting genotoxins
  • the incorporation of S9 fraction to identify metabolically activated genotoxins
  • distinguishing between clastogens and aneugens

Read our poster to learn more about our research!

LEARN MORE

 

 

 

Tags: Posters, Toxicology & Safety

Investigating Rosuvastatin DDI Prediction

Posted by Evotec on Feb 11, 2021 7:55:59 PM

Rosuvastatin is used in the treatment of dyslipidemia. The drug transporter BCRP (breast cancer resistant protein) has been identified as the rate limiting barrier to rosuvastatin absorption.

In this poster, we focus on:

  • whether estrone 3-sulfate can be applied as a surrogate in vitro BCRP probe substrate for predicting rosuvastatin DDI 
  • a comparison of BCRP inhibition assessment using rosuvastatin or estrone 3-sulfate as probe substrate for six established BCRP inhibitors for which a clinical DDI with rosuvastatin has been characterised

Read our poster to learn more about our research!

LEARN MORE

 

 

 

Tags: Posters, ADME/DMPK

Comparing In Vitro Mitochondrial Toxicity Assays

Posted by Evotec on Feb 11, 2021 7:49:56 PM

Mitochondria are a common target for drug-induced toxicity. Several different in vitro methods exist for investigating drug-induced mitochondrial toxicity. 

In this poster, we focus on:

  • a comparison of three different in vitro assays for detecting mitochondrial toxicity (Glu/Gal cytotoxicity assay, Seahorse Flux Analyser and high content imaging of mitochondrial membrane potential)
  • the effect of protein binding on the mitochondrial toxicity
  • recommendations for a tiered screening approach

Read our poster to learn more about our research!

LEARN MORE

 

 

 

Tags: Posters, Toxicology & Safety

DILI Prediction using Human 3D Models, HCS and Concentration Normalisation

Posted by Evotec on Feb 11, 2021 7:48:54 PM

In vitro 3D cell-based models are more representative of the complex in vivo microenvironment than traditional 2D monolayers. Furthermore, these models allow for long term compound exposures - more closely replicating clinical dosing strategies.

In this poster, we focus on:

  • 3D human liver microtissues formed from multiple donors co-cultured with human non-parenchymal cells
  • exposure of the cells to multiple doses of hepatotoxins and non-hepatotoxins
  • HCS analysis of DNA structure, GSH content, ROS formation and mitochondrial function
  • the impact of correcting for therapeutically relevant tissue Cmax 

Read our poster to learn more about our research!

LEARN MORE

 

Tags: Posters, Toxicology & Safety

Detecting BMS-986094 Cardiotoxicity using Chronic Multiplatform Assay

Posted by Evotec on Feb 11, 2021 7:16:08 PM

BMS-986094 (INX-08189) is a prodrug of a guanosine nucleotide analogue which was developed to treat hepatitis C virus but was discontinued during clinical trials due to cardiotoxic effects.

In this poster, we focus on:

  • the mechanism of BMS-986094 cardiotoxicity 
  • the impact of chronic dosing over multiple time points
  • evaluation of data from an MEA platform, a cardiac mitochondrial protein biogenesis assay, a calcium flux assay and a cardiac cytotoxicity assay 

Read our poster to learn more about our research!

LEARN MORE

 

Tags: Posters, Toxicology & Safety

Understanding BMS-986094 Cardiotoxicity using Human iPSC-Derived Cardiomyocytes

Posted by Evotec on Feb 11, 2021 6:27:44 PM

BMS-986094 (INX-08189) is a guanosine nucleotide analogue prodrug which was developed to treat hepatitis C virus (HCV). However, BMS-986094 was discontinued in Phase III clinical trials with 1 death and 8 people hospitalised with significantly reduced left ventricular ejection fraction (LVEF). Cardiotoxic effects were observed in 14 out of the 34 patients with left ventricular dysfunction, with ST depressions, T-wave inversions or loss of T-wave amplitude.

In this poster, we focus on:

  • investigating the mechanism behind the cardiotoxicity of BMS-986094
  • the use of MEA and human iPSC-derived cardiomyocytes in long term incubations with BMS-986094

Read our poster to learn more about our research!

LEARN MORE

 

 

Tags: Posters, Toxicology & Safety

In Vitro 3D Heart - Microtissue Model for Understanding Cardiotoxicity

Posted by Evotec on Feb 11, 2021 6:09:41 PM

In vitro 3D microtissue models are transforming our understanding of cardiotoxicity.

In this poster, we focus on:

  • the use of a 3D cardiac triculture model consisting of iPSC-derived cardiomyocytes, cardiovascular endothelial cells and cardiac fibroblasts in cardiotoxicity prediction
  • the detection of functional and structural mechanisms of cardiotoxicity
  • calcium flux as a sensitive detection method for cardiac contraction as well as microtissue area for identifying cardiac hypertrophy
  • HCS detection of cell health markers such as mitochondrial function, calcium homeostasis and nuclei/DNA structure

Read our poster to learn more about our research!

LEARN MORE

 

 

 

Tags: Posters, Toxicology & Safety